Anti-CD22 Therapies - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Anti-CD22 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD22 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anti-CD22 Therapies: Overview
CD22 (Siglec 2) is a single-spanning membrane glycoprotein of 140 kDa on the surface of B cells. Plasma cells do not express the molecule. CD22 has seven extracytoplasmic Ig-like domains and belongs to the Ig superfamily. It serves as a receptor for carbohydrate determinants on a wide variety of cell surface and soluble molecules in vivo. In contrast to CD19, CD22 can act as an antagonist to B cell activation most likely by enhancing the threshold of BCR induced signals. CD22 is expressed on the surface of most B-cell leukemias and lymphomas and therefore has been explored as a target for Ab-based therapies. Research studies shows that use of chimeric antigen receptor (CAR) T-cell therapy, specific for CD22 was reported to provide high response rates for patients with B-cell acute lymphoblastic leukemia (B-ALL) who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment. The ability of CD22 to regulate both BCR and TLRs represents an attractive therapeutic strategy for manipulating B cell responses in autoimmunity.
Report Highlights
This segment of the Anti-CD22 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD22 Therapies Emerging Drugs
Further product details are provided in the report……..
Anti-CD22 Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD22 Therapies drugs segregated based on following parameters that define the scope of the report, such as:
Anti-CD22 Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD22 Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD22 Therapies drugs.
Anti-CD22 Therapies Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Anti-CD22 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD22 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anti-CD22 Therapies: Overview
CD22 (Siglec 2) is a single-spanning membrane glycoprotein of 140 kDa on the surface of B cells. Plasma cells do not express the molecule. CD22 has seven extracytoplasmic Ig-like domains and belongs to the Ig superfamily. It serves as a receptor for carbohydrate determinants on a wide variety of cell surface and soluble molecules in vivo. In contrast to CD19, CD22 can act as an antagonist to B cell activation most likely by enhancing the threshold of BCR induced signals. CD22 is expressed on the surface of most B-cell leukemias and lymphomas and therefore has been explored as a target for Ab-based therapies. Research studies shows that use of chimeric antigen receptor (CAR) T-cell therapy, specific for CD22 was reported to provide high response rates for patients with B-cell acute lymphoblastic leukemia (B-ALL) who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment. The ability of CD22 to regulate both BCR and TLRs represents an attractive therapeutic strategy for manipulating B cell responses in autoimmunity.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD22 Therapies R&D. The therapies under development are focused on novel approaches for Anti-CD22 Therapies.
This segment of the Anti-CD22 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD22 Therapies Emerging Drugs
- SM03: SinoMab Bioscience
- AUTO3: Autolus
Further product details are provided in the report……..
Anti-CD22 Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD22 Therapies drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Anti-CD22 Therapies
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Anti-CD22 Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD22 Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD22 Therapies drugs.
Anti-CD22 Therapies Report Insights
- Anti-CD22 Therapies Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Anti-CD22 Therapies drugs?
- How many Anti-CD22 Therapies drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD22 Therapies?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD22 Therapies therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anti-CD22 Therapies and their status?
- What are the key designations that have been granted to the emerging drugs?
- SinoMab Bioscience
- Autolus
- Shanghai Unicar-Therapy Bio-medicine Technology
- Cellectis
- Allife Medical Science and Technology
- SM03
- AUTO3
- Anti CD22 chimeric antigen receptor T cell therapy
- UCART 22
- Anti-CD22 CAR NK Cells
Introduction
Executive Summary
Anti-CD22 Therapies: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD22 Therapies – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD22 Therapies companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD22 Therapies Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SM03: SinoMab Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Anti CD22 chimeric antigen receptor T cell therapy: Shanghai Unicar-Therapy Bio-medicine Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
AUTO3: Autolus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Anti-CD22 Therapies Key Companies
Anti-CD22 Therapies Key Products
Anti-CD22 Therapies- Unmet Needs
Anti-CD22 Therapies- Market Drivers and Barriers
Anti-CD22 Therapies- Future Perspectives and Conclusion
Anti-CD22 Therapies Analyst Views
Anti-CD22 Therapies Key Companies
Appendix
Executive Summary
Anti-CD22 Therapies: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD22 Therapies – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD22 Therapies companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD22 Therapies Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SM03: SinoMab Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Anti CD22 chimeric antigen receptor T cell therapy: Shanghai Unicar-Therapy Bio-medicine Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
AUTO3: Autolus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Anti-CD22 Therapies Key Companies
Anti-CD22 Therapies Key Products
Anti-CD22 Therapies- Unmet Needs
Anti-CD22 Therapies- Market Drivers and Barriers
Anti-CD22 Therapies- Future Perspectives and Conclusion
Anti-CD22 Therapies Analyst Views
Anti-CD22 Therapies Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anti-CD22 Therapies
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anti-CD22 Therapies
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anti-CD22 Therapies
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anti-CD22 Therapies
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
